$QURE News

UniQure Q1 Earnings Review: Limited Progress With FDA, But UK Approval In Play

HC Wainwright & Co. Maintains Buy on uniQure, Lowers Price Target to $50

uniQure N.V. (QURE) Q1 2026 Earnings Call Transcript

Transcript: uniQure Q1 2026 Earnings Conference Call

uniQure Q1 EPS $(0.85), Inline, Sales $3.562M Miss $5.223M Estimate

Chardan Capital Maintains Buy on uniQure, Raises Price Target to $37

uniQure Announces Meeting With UK MHRA And Plans To Submit Marketing Authorization Application For AMT-130 For The Treatment Of Huntington's Disease In Q3 2026

Goldman Sachs Maintains Neutral on uniQure, Raises Price Target to $10

Is Regulatory Scrutiny of AMT-130 Quietly Rewriting uniQure’s (QURE) Gene Therapy Investment Story?

Barclays Reaffirms Equal Weight Rating for uniQure (QURE)

Nurix Therapeutics (NRIX) Moves 6.9% Higher: Will This Strength Last?

Barclays Maintains Equal-Weight on uniQure, Lowers Price Target to $25

A Unique Situation For UniQure

Mizuho Upgrades uniQure to Outperform, Raises Price Target to $35

uniQure Shares Surge 26% On US FDA Shakeup Even As Momentum Tumbles: Will New Leadership Greenlight Huntington's Therapy?

HC Wainwright & Co. Reiterates Buy on uniQure, Maintains $70 Price Target

Chardan Capital Maintains Buy on uniQure, Raises Price Target to $31

What the Options Market Tells Us About uniQure

uniQure stock surges 36% on FDA official’s departure

uniQure shares are trading higher after multiple analyst firms upgraded their rating and raised their respective price targets on the stock.